Table 2 Associations of osteoprotegerin and fetuin-A in the univariate analysis
A) Mann-Whitney U-test | ||||
Osteoprotegerin | Fetuin-A | |||
Variable | Median (interquartile range) | P-Value | Median (interquartile range) | P-Value |
Previous Transplant | ||||
Yes | 9.77 (5.14–14.27) | 0.944 | 44.1 (30.18–58.51) | 0.022 |
No | 8.58 (6.21–12.69) | 35.24 (25.55–49.83) | ||
Diabetes Mellitus | ||||
Yes | 9.29 (7.06–11.76) | 0.575 | 31.12 (20.8–43.94) | 0.008 |
No | 8.63 (5.72–13.01) | 37.46 (28.04–54.02) | ||
Left Ventricular Hypertrophy | ||||
Yes | 10.02 (7.6–12.88) | 0.068 | 34.92 (26.13–51.19) | 0.639 |
No | 8.23 (5.65–12.99) | 37.02 (26.93–51.97) | ||
Arrhythmia | ||||
Yes | 12.1 (6.89–15.1) | 0.009 | 35.17 (26.79–55.41) | 0.916 |
No | 8.26 (5.91–11.85) | 37.02 (26.50–50.89) | ||
Statin treatment | ||||
Yes | 7.93 (6.1–10.62) | 0.086 | 35.17 (24.21–54.02) | 0.631 |
No | 9.67 (6.05–13.43) | 37.02 (26.87–50.75) | ||
ACEI/ ARB treatment | ||||
Yes | 7.84 (5.03–11.30) | 0.059 | 39.99 (33.68–57.52) | 0.078 |
No | 9.08 (6.38–13.04) | 35.17 (26.11–50.89) | ||
Beta-blockers treatment | ||||
Yes | 7.27 (4.99–11.49) | 0.038 | 37.03 (27.35–54.98) | 0.920 |
No | 9.08 (6.39–13.04) | 36.58 (26.50–50.92) | ||
Carotid Plaques | ||||
Yes | 8.5 (6.1–12.69) | 0.002 | 31.24 (23.48–44.91) | 0.728 |
No | 5.98 (3.41–7.77) | 35.34 (22.37–51.71) | ||
Calcified Plaques | ||||
Yes | 8.22 (6.23–12.66) | 0.038 | 30.14 (23.49–44.34) | 0.378 |
No | 6.94 (4.97–10.64) | 37.04 (21.54–51.46) | ||
Severe Degrees of CAD | ||||
Yes | 8.5 (6.1–12.69) | 0.002 | 31.24 (23.48–44.91) | 0.728 |
No | 5.98 (3.41–7.77) | 35.34 (22.37–51.71) | ||
B) Spearman rank correlation test | ||||
Osteoprotegerin | Fetuin-A | |||
Variable | Rho Spearman | P-Value | Rho Spearman | P-Value |
Age (years) | 0.383 | < 0.001 | −0.161 | 0.018 |
LV mass (gr) | 0.126 | 0.117 | −0.19 | 0.020 |
LV ejection Fraction (%) | −0.206 | 0.01 | −0.056 | 0.491 |
Charlson Comorbility Index | 0.38 | < 0.001 | −0.14 | 0.040 |
Calcium (mg/dl) | 0.115 | 0.088 | −0.015 | 0.828 |
Phosphate (mg/dl) | −0.245 | < 0.001 | 0.011 | 0.870 |
iPTH (pg/ml) | −0.118 | 0.083 | −0.083 | 0.228 |
Ca-P product | −0.2 | 0.003 | 0.012 | 0.861 |
Dose of calcium salts (gr/day) | −0.016 | 0.816 | 0.207 | 0.003 |
Creatinine (mg/dl) | −0.224 | 0.001 | 0.096 | 0.161 |
BUN (mg/dl) | −0.156 | 0.039 | 0.017 | 0.824 |
Troponin I (ng/ml) | 0.207 | 0.003 | −0.071 | 0.312 |
BNP (pg/ml) | 0.305 | < 0.001 | −0.091 | 0.182 |
Systolic Blood Pressure (mmHg) | −0.008 | 0.907 | −0.017 | 0.805 |
Diastolic Blood Pressure (mmHg) | −0.081 | 0.243 | −0.028 | 0.690 |
Mean Blood Pressure (mmHg) | −0.049 | 0.479 | −0.025 | 0.727 |
Adiponectin (μg/ml) | 0.237 | < 0.001 | −0.04 | 0.558 |
IL-6 (pg/ml) | 0.075 | 0.291 | −0.16 | 0.027 |
CRP (mg/dl) | 0.062 | 0.362 | −0.013 | 0.846 |
Malondialdehyde (mMol/L) | 0.086 | 0.205 | 0.179 | 0.009 |
Homocysteine (μmol/L) | −0.021 | 0.757 | −0.137 | 0.047 |
ADMA (μmol/L) | −0.034 | 0.625 | 0.143 | 0.040 |
Carotid Intima-media thickness (mm) | 0.234 | 0.034 | −0.071 | 0.529 |